Stoke Therapeutics Reports Strong 2025 Financials with Reduced Net Loss and Pipeline Advancement
STOK has more than doubled off its 52-week low of $5.35.
Summary
Stoke Therapeutics reported a significant reduction in net loss and a substantial increase in revenue for 2025, extending its cash runway into 2028, alongside continued clinical progress for its lead drug candidates.
Key Events · Earnings and Guidance · STOK
-
Significant Financial Improvement in 2025
The company reported a net loss of $6.9 million for the year ended December 31, 2025, a substantial improvement from a net loss of $89.0 million in 2024. Revenue surged to $184.4 million in 2025 from $36.6 million in 2024, primarily driven by the Biogen collaboration.
-
Extended Cash Runway into 2028
Stoke Therapeutics ended 2025 with $390.9 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028.
-
Advancement of Lead Clinical Programs
The global Phase 3 EMPEROR study for zorevunersen (STK-001) in Dravet syndrome initiated in May 2025, with enrollment expected to complete in Q2 2026 and pivotal data anticipated in mid-2027. The Phase 1 OSPREY study for STK-002 in Autosomal Dominant Optic Atrophy (ADOA) dosed its first patient in February 2026.
-
Acadia Collaboration Program Terminations
Acadia Pharmaceuticals Inc. terminated the MECP2 and an undisclosed neurodevelopmental program effective September 3, 2025, resulting in Stoke Therapeutics losing eligibility for up to $662.5 million in potential milestones from these programs. The SYNGAP1 collaboration with Acadia remains ongoing.
Analysis · STOK · Life Sciences
Stoke Therapeutics' 2025 annual report highlights a significant financial turnaround, driven by a substantial increase in revenue and a dramatic reduction in net loss. The company's cash position provides a solid runway into 2028, supporting ongoing clinical development for its lead programs. While the termination of certain Acadia collaboration programs is a setback, the progress in the Phase 3 EMPEROR study for Dravet syndrome and the initiation of the Phase 1 OSPREY study for ADOA demonstrate continued pipeline advancement. The adoption of multiple Rule 10b5-1 plans by insiders is a notable, albeit pre-planned, selling signal.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, STOK was trading at $33.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $5.35 to $40.22. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.